Synthesis, characterization, biological activity, DNA and BSA binding study: novel copper(ii) complexes with 2-hydroxy-4-aryl-4-oxo-2-butenoate.

A serie of novel square pyramidal copper(ii) complexes [Cu(L)2H2O] (3a-d) with O,O-bidentate ligands [L = ethyl-2-hydroxy-4-aryl-4-oxo-2-butenoate; aryl = 3-methoxyphenyl-2a, (E)-2-phenylvinyl-2b, (E)-2-(4'-hydroxy-3'-methoxyphenyl)vinyl-2c, 3-nitrophenyl-2d, 2-thienyl-2e] were synthesized and characterized by spectral (UV-Vis, IR, ESI-MS and EPR), elemental and X-ray analysis. The antimicrobial activity was estimated by the determination of the minimal inhibitory concentration (MIC) using the broth microdilution method. The most active antibacterial compounds were 3c and 3d, while the best antifungal activity was showed by complexes 3b and 3e. The lowest MIC value (0.048 mg mL-1) was measured for 3c against Proteus mirabilis. The cytotoxic activity was tested using the MTT method on human epithelial carcinoma HeLa cells, human lung carcinoma A549 cells and human colon carcinoma LS174 cells. All complexes showed extremely better cytotoxic activity compared to cisplatin at all tested concentrations. Compound 3d expressed the best activity against all tested cell lines with IC50 values ranging from 7.45 to 7.91 μg mL-1. The type of cell death and the impact on the cell cycle for 3d and 3e were evaluated by flow cytometry. Both compounds induced apoptosis and S phase cell cycle arrest. The interactions between selected complexes (3d and 3e) and CT-DNA or bovine serum albumin (BSA) were investigated by the fluorescence spectroscopic method. Competitive experiments with ethidium bromide (EB) indicated that 3d and 3e have a propensity to displace EB from the EB-DNA complex through intercalation suggesting strong competition with EB [Ksv = (1.4 ± 0.2) and (2.9 ± 0.1) × 104 M-1, respectively]. Ksv values indicate that these complexes bind to DNA covalently and non-covalently. The achieved results in the fluorescence titration of BSA with 3d and 3e [Ka = (2.9 ± 0.2) × 106 and (2.5 ± 0.2) × 105 M, respectively] showed that the fluorescence quenching of BSA is a result of the formation of the 3d- and 3e-BSA complexes. The obtained Ka values are high enough to ensure that a significant amount of 3d and 3e gets transported and distributed through the cells.

[1]  James P. Hall,et al.  Direct observation by time-resolved infrared spectroscopy of the bright and the dark excited states of the [Ru(phen)2(dppz)]2+ light-switch compound in solution and when bound to DNA in and when , 2017 .

[2]  I. Matić,et al.  Synthesis, characterization, cytotoxicity and antiangiogenic activity of copper(II) complexes with 1-adamantoyl hydrazone bearing pyridine rings. , 2016, European journal of medicinal chemistry.

[3]  M. Kosanić,et al.  Solvent-free synthesis of novel vanillidene derivatives of Meldrum's acid: biological evaluation, DNA and BSA binding study , 2016 .

[4]  A. Arsenijević,et al.  DNA binding properties, histidine interaction and cytotoxicity studies of water soluble ruthenium(ii) terpyridine complexes. , 2016, Dalton transactions.

[5]  G. Bogdanović,et al.  Vanillic aldehydes for the one-pot synthesis of novel 2-oxo-1,2,3,4-tetrahydropyrimidines , 2016, Molecular Diversity.

[6]  Changhao Wang,et al.  Terpyridine–Cu(ii) targeting human telomeric DNA to produce highly stereospecific G-quadruplex DNA metalloenzyme , 2015, Chemical science.

[7]  Sheng Lin,et al.  Metal complexes as potential modulators of inflammatory and autoimmune responses , 2014, Chemical science.

[8]  Nenad Ž. Janković,et al.  Double catalytic effect of (PhNH3)2CuCl4 in a novel, highly efficient synthesis of 2-oxo and thioxo-1,2,3,4-tetra-hydopyrimidines , 2015 .

[9]  L. Oprean,et al.  Bovine Serum Albumin Interactions with Metal Complexes , 2014, Clujul medical.

[10]  W. Berger,et al.  NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application , 2014 .

[11]  A. Kapdi,et al.  Anti-cancer palladium complexes: a focus on PdX2L2, palladacycles and related complexes. , 2014, Chemical Society reviews.

[12]  Wen Zhou,et al.  A mitochondrion-targeting copper complex exhibits potent cytotoxicity against cisplatin-resistant tumor cells through multiple mechanisms of action , 2014 .

[13]  É. Cavalheiro,et al.  Using of a graphite-polyurethane composite electrode modified with a Schiff base as a bio-inspired sensor in the dopamine determination , 2014 .

[14]  R. Scopelliti,et al.  Conformational control of anticancer activity: the application of arene-linked dinuclear ruthenium(II) organometallics , 2014 .

[15]  Mateo I. Sánchez,et al.  Metal-catalyzed uncaging of DNA-binding agents in living cells† †Electronic supplementary information (ESI) available: Synthesis and characterization of the studied molecules and required precursors. NMR, UV, and fluorescence spectra, titrations, control experiments, and detailed procedures for cell , 2014, Chemical science.

[16]  V. Gandin,et al.  Advances in copper complexes as anticancer agents. , 2014, Chemical reviews.

[17]  J. L. M. Cid,et al.  Metal-catalyzed uncaging of DNA-binding agents in living cells , 2014 .

[18]  C. Smythe,et al.  Targeting the endoplasmic reticulum with a membrane-interactive luminescent ruthenium(ii) polypyridyl complex , 2013, Chemical science.

[19]  Weiqun Zhou,et al.  Crystal structures and antimicrobial activities of copper(II) complexes of fluorine-containing thioureido ligands , 2013 .

[20]  J. Joseph,et al.  Synthesis, characterization and antimicrobial activities of copper complexes derived from 4-aminoantipyrine derivatives , 2013 .

[21]  Ying Guo,et al.  Synthesis and neuroprotective effect of E-3,4-dihydroxy styryl aralkyl ketones derivatives against oxidative stress and inflammation. , 2013, Bioorganic & medicinal chemistry letters.

[22]  N. Dharmaraj,et al.  Potentially cytotoxic new copper(II) hydrazone complexes: synthesis, crystal structure and biological properties. , 2013, Dalton transactions.

[23]  V. Pichler,et al.  Novel metal(II) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents , 2013 .

[24]  P. Sadler,et al.  The contrasting chemical reactivity of potent isoelectronic iminopyridine and azopyridine osmium(II) arene anticancer complexes , 2012 .

[25]  N. Arsenijević,et al.  Cytotoxic properties of platinum(IV) and dinuclear platinum(II) complexes and their ligand substitution reactions with guanosine-5′-monophosphate , 2012, Transition Metal Chemistry.

[26]  F. Siu,et al.  Anticancer dirhodium(II,II) carboxylates as potent inhibitors of ubiquitin-proteasome system , 2012 .

[27]  Y. Lam,et al.  Osmium(VI) nitrido complexes bearing azole heterocycles: a new class of antitumor agents , 2012 .

[28]  T. Kanjevac,et al.  Cytotoxicity of gold(III) complexes on A549 human lung carcinoma epithelial cell line. , 2012, Medicinal chemistry (Shariqah (United Arab Emirates)).

[29]  Bao-dui Wang,et al.  Crystal structures, DNA-binding and cytotoxic activities studies of Cu(II) complexes with 2-oxo-quinoline-3-carbaldehyde Schiff-bases. , 2010, European journal of medicinal chemistry.

[30]  G. Ramesh,et al.  Mechanisms of Cisplatin Nephrotoxicity , 2010, Toxins.

[31]  D. M. Yufanyi,et al.  Synthesis, characterisation and antimicrobial activities of cobalt(II), copper(II) and zinc(II) mixed-ligand complexes containing 1,10-phenanthroline and 2,2’-bipyridine , 2010 .

[32]  S. Kaisarevic,et al.  ANTICANCER ACTIVITY OF NEW COPPER(II) COMPLEXES INCORPORATING A PYRIDOXAL-SEMICARBAZONE LIGAND , 2010 .

[33]  A. Hartwig.  The role of DNA repair in benzene-induced carcinogenesis. , 2010, Chemico-biological interactions.

[34]  C. Marzano,et al.  Copper in diseases and treatments, and copper‐based anticancer strategies , 2009, Medicinal research reviews.

[35]  F. Ahmadi,et al.  In vitro study of damaging effects of 2,4-dichlorophenoxyacetic acid on DNA structure by spectroscopic and voltammetric techniques. , 2009, DNA and cell biology.

[36]  C. Marzano,et al.  Copper complexes as anticancer agents. , 2009, Anti-cancer agents in medicinal chemistry.

[37]  Howard L McLeod,et al.  Platinum neurotoxicity pharmacogenetics , 2009, Molecular Cancer Therapeutics.

[38]  N. Hadjiliadis,et al.  Antiproliferative and anti-tumor activity of organotin compounds , 2009 .

[39]  F. Ahmadi,et al.  In vitro study of DNA interaction with clodinafop-propargyl herbicide. , 2008, DNA and Cell Biology.

[40]  V. Farkaš.  Structure and biosynthesis of fungal cell walls: Methodological approaches , 2008, Folia Microbiologica.

[41]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[42]  S. Fricker.  Metal based drugs: from serendipity to design. , 2007, Dalton transactions.

[43]  T. Hambley.  Developing new metal-based therapeutics: challenges and opportunities. , 2007, Dalton transactions.

[44]  L. Strekowski,,et al.  Noncovalent interactions with DNA: an overview. , 2007, Mutation research.

[45]  M. Harding,et al.  Antitumour bis(cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives. , 2007, Dalton transactions.

[46]  L. Nahar,et al.  Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the in vitro antibacterial screening of phytochemicals , 2007, Methods.

[47]  P. Sadler,et al.  Using coordination chemistry to design new medicines , 2007 .

[48]  J. Dilworth,et al.  Complexation versus thiadiazole formation for reactions of thiosemicarbazides with copper(II). , 2007, Dalton transactions.

[49]  R. Gust,et al.  Non Platinum Metal Complexes as Anti‐cancer Drugs , 2007, Archiv der Pharmazie.

[50]  Yi Liu,et al.  Studies on the interaction between Oxaprozin-E and bovine serum albumin by spectroscopic methods. , 2006, International journal of biological macromolecules.

[51]  Bernhard Lippert,et al.  Cisplatin : chemistry and biochemistry of a leading anticancer drug , 2006 .

[52]  Robin Taylor,et al.  Mercury: visualization and analysis of crystal structures , 2006 .

[53]  R. Gatti,et al.  Non-apoptotic programmed cell death induced by a copper(II) complex in human fibrosarcoma cells , 2006, Histochemistry and Cell Biology.

[54]  O. Ijare,et al.  Study of the interaction of an anticancer drug with human and bovine serum albumin: spectroscopic approach. , 2006, Journal of pharmaceutical and biomedical analysis.

[55]  Mika Kettunen,et al.  Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. , 2006, Current medicinal chemistry.

[56]  S. Kellie,et al.  SEVERE NEUROTOXICITY, OTOTOXICITY AND NEPHROTOXICITY FOLLOWING HIGH-DOSE CISPLATIN AND AMIFOSTINE , 2005, Pediatric hematology and oncology.

[57]  Arabinda Mallick,et al.  Fluorometric investigation of interaction of 3-acetyl-4-oxo-6,7-dihydro-12H indolo-[2,3-a] quinolizine with bovine serum albumin. , 2004, Biophysical chemistry.

[58]  R. Gust,et al.  Development of cobalt(3,4-diarylsalen) complexes as tumor therapeutics. , 2004, Journal of medicinal chemistry.

[59]  C. Bokemeyer,et al.  A Randomized Trial Comparing the Nephrotoxicity of Cisplatin/Ifosfamide-Based Combination Chemotherapy with or without Amifostine in Patients with Solid Tumors , 2000, Investigational New Drugs.

[60]  Z. Darżynkiewicz,et al.  DNA Damage Induced by DNA Topoisomerase I- and Topoisomerase II- Inhibitors Detected by Histone H2AXphosphorylation in Relation to the Cell Cycle Phase and Apoptosis , 2003, Cell cycle.

[61]  Hans-Peter Lipp,et al.  Toxicity of platinum compounds , 2003, Expert opinion on pharmacotherapy.

[62]  Anthony L. Spek,et al.  Journal of , 1993 .

[63]  M. Tegoni,et al.  Synthesis, molecular structure, solution equilibrium, and antiproliferative activity of thioxotriazoline and thioxotriazole complexes of copper II and palladium II. , 2002, Journal of inorganic biochemistry.

[64]  Carlo Bertucci,et al.  Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. , 2002, Current medicinal chemistry.

[65]  P. Brennan,et al.  Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis. , 2001, Glycobiology.

[66]  J. Heijenoort.  Formation of the glycan chains in the synthesis of bacterial peptidoglycan , 2001 .

[67]  M. Kasten,et al.  Cell cycle and apoptosis. , 2000, Neoplasia.

[68]  W. Denny,et al.  Cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure-activity relationships. , 1999, Journal of inorganic biochemistry.

[69]  E. Spodine,et al.  Syntheses and characterization of copper(II) complexes with Schiff-base ligands derived from ethylenediamine, diphenylethylenediamine and nitro, bromo and methoxy salicylaldehyde , 1999 .

[70]  David D. Christ,et al.  Chapter 33. Plasma Protein Binding of Drugs , 1996 .

[71]  M. Nardelli,et al.  PARST95 – an update to PARST: a system of Fortran routines for calculating molecular structure parameters from the results of crystal structure analyses , 1995 .

[72]  D C Carter,et al.  Structure of serum albumin. , 1994, Advances in protein chemistry.

[73]  D. Kahne,et al.  Studies of the 2:1 chromomycin A3-Mg2+ complex in methanol: role of the carbohydrates in complex formation , 1993 .

[74]  D. McMillin,et al.  Spectroscopic and photophysical studies of the binding interactions between copper phenanthroline complexes and RNA , 1993 .

[75]  P. Sadler.  Inorganic Chemistry and Drug Design , 1991 .

[76]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[77]  M. Mahajan,et al.  ESR study of Cu(II) complexes , 1981 .

[78]  J. Olmsted,et al.  Mechanism of ethidium bromide fluorescence enhancement on binding to nucleic acids. , 1977, Biochemistry.

[79]  J. Lakowicz,et al.  Quenching of fluorescence by oxygen. A probe for structural fluctuations in macromolecules. , 1973, Biochemistry.

[80]  B. Hathaway,et al.  The electronic properties and stereochemistry of mono-nuclear complexes of the copper(II) ion , 1970 .